New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
12:38 EDTGILDGilead announces interim data from the ongoing Phase 2 ELECTRON study
Gilead Sciences announced interim data from the ongoing Phase 2 ELECTRON study examining a 12-week course of therapy with the investigational nucleotide sofosbuvir (formerly referred to as GS-7977), the NS5A inhibitor GS-5885 and ribavirin in patients with genotype 1 chronic hepatitis C virus (HCV) infection. Among treatment-naïve patients receiving this combination, 100 percent (n=25/25) remained HCV RNA undetectable four weeks after completing therapy, SVR4. These data will be presented on Tuesday, November 13th at the 63rd annual meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2012) in Boston. “These results indicate that adding GS-5885 to sofosbuvir-based regimens may enhance SVR rates, potentially offering HCV genotype 1 infected patients a convenient 12-week course of oral therapy,” said Professor Edward Gane, MD, Deputy Director and Hepatologist, New Zealand Liver Transplant Unit, Auckland City Hospital in New Zealand, and principal investigator of the ELECTRON study. “Along with other data from the ELECTRON study, these results add to the growing body of evidence supporting the potential for effective sofosbuvir-based all-oral regimens.”
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
09:39 EDTGILDActive equity options trading
Subscribe for More Information
November 24, 2014
16:00 EDTGILDOptions Update; November 24, 2014
Subscribe for More Information
10:16 EDTGILDGilead management to meet with ISI Group
Meeting to be held in Scotland on December 1 hosted by ISI Group.
09:39 EDTGILDActive equity options trading
Subscribe for More Information
November 21, 2014
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL AMZN TSLA BIDU CLF DOW LVS BABA TWTR GILD
November 20, 2014
15:44 EDTGILDOptions Update; November 20, 2014
Subscribe for More Information
11:21 EDTGILDGilead calls active on renewed activist investor speculation
Gilead November 101 and 103 calls are active on 14K contracts (2K puts) on renewed activist investor speculation. November call option implied volatility is at 38, December is at 36, and January is at 35; compared to its 26-week average of 33 according to Track Data. Active call volume suggests traders taking positions for larger near term price movement.
11:11 EDTGILDRumor: Gilead moves up on renewed activiest investor speculation
Shares of Gilead are moving higher on speculation that Carl Icahn has taken a stake in the company.
November 19, 2014
07:33 EDTGILDGilead Q4 HCV sales likely to reach at least $3.5B, says Wells Fargo
Subscribe for More Information
November 18, 2014
16:00 EDTGILDOptions Update; November 18, 2014
iPath S&P 500 VIX Short-Term Futures down 48c to 28.09. Option volume leaders: AAPL TSLA TWTR KO PBR GILD according to Track Data.
10:08 EDTGILDGilead granted European Commission marketing authorization for Harvoni
Subscribe for More Information
November 17, 2014
16:00 EDTGILDOptions Update; November 17, 2014
Subscribe for More Information
11:06 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL PBR BHI GILD MU HD AMZN TSLA YHOO FB TWTR
November 14, 2014
14:53 EDTGILDCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
11:48 EDTGILDStocks with call strike movement; GILD BBY
Subscribe for More Information
09:38 EDTGILDActive equity options trading
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use